Publications

Export 353 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J [K] L M N O P Q R S T U V W X Y Z   [Show ALL]
K
Kaiser, T. R. M., and ahmed tarek elsharkawy, "THE KEY: A PILOT STUDY OF A NOVEL TECHNIQUE FOR CONSERVATIVE EXTRACTION OF REMAINING ROOTS", EDS, vol. 63, issue 1, 2016.
Kamal, A., M. Salama, A. Kamal, A. Mohsen, and I. Siam, "Klotho (rs1207568 and rs564481) Gene Variants and Colorectal Cancer Risk", Turkish Journal of Gastroenterology, vol. 31, no. 7: AVES, pp. 497-502, 2020. AbstractWebsite

Background/Aims: Whereas colorectal cancer (CRC) is the third most common cancer worldwide, klotho gene has been reported as a tumor suppressor gene. Therefore, the aim of this study was to investigate the association between klotho (rs1207568 and rs564481) variants and CRC in Egyptian patients. Materials and Methods: A case-control study comprising 100 patients with CRC and 100 age- and sex-matched healthy controls was conducted. Genotyping of klotho was performed by polymerase chain reaction with confronting two-pair primers. Results: The frequencies of the A allele of rs1207568 and the AC haplotype were significantly higher in patients with CRC than in the controls (p=0.019 and p=0.005, respectively). Conclusion: We propose that klotho (rs1207568 and rs564481) variants play a significant role in colorectal carcinogenesis and that the klotho protein could be a target for oncotherapy. © Copyright 2020 by The Turkish Society of Gastroenterology

KAMAL, K. A. R. E. E. M., H. Hefny, A. E. Hassanien, and M. Tolba, "Kekre’s Transform for Protecting Fingerprint Template.", 13th IEEE International Conference on Hybrid Intelligent Systems |(HIS13) Tunisia, 4-6 Dec. pp. 186-191, 2013, Tunisia, , 4-6 Dec, 2013.
Kamal, A., M. Salama, A. Kamal, A. Mohsen, and I. Siam, "Klotho (rs1207568 and rs564481) Gene Variants and Colorectal Cancer Risk", Turkish Journal of Gastroenterology, vol. 31, no. 7, pp. 497-502, 2020. AbstractWebsite
n/a
Kashif, K. E. F., A. - R. Hazem, M. A. Rozik, and H. A. Abdallah, "Kashif, K. E. F., A. - R. Hazem, M. A. Rozik, and H. A. Abdallah, "Strengthening of Deficient RC Columns Subjected To Concentric and Eccentric Loads",.", Journal of advances in Structural Engineering, vol. 23, issue 7, pp. 1322-1335, 2020.
Khalek, A. A. A., M. M. Hefny, A. S. Mogoda, and G. A. El-Mahdy, "Kinetics of dissolution and impedance behavior of anodic oxide films on hafnium in oxalate media.", J. Fac. Sci., UAE Univ., vol. 7, pp. 38, 1995.
Khamiss, O., A. El-Helaly, E. dessouky Ammar, and S. A. Ela, "Karyotyping characterization of continous new cell line from pupae ovaries of Egyptian cotton leaf worm Spodoptera littoralis (SL-OMI) adapted on 27C", Journal of agricultural science, vol. 30, issue 4, pp. 2229-2243, 2005. 2.pdf
Koeck, J., Y. Abo-Madyan, H. T. Eich, F. Stieler, J. Fleckenstein, J. Kriz, R. - P. Mueller, F. Wenz, and F. Lohr, "Klinische Relevanz verschiedener Strategien zur Dosisberechnung für die IMRT des mediastinalen Hodgkin-Lymphoms", Strahlentherapie und Onkologie, vol. 188: Springer-Verlag, pp. 653–659, 2012. Abstract
n/a
Korany, E. S., O. M. Helmy, E. A. M. Halawany, Y. E. Ragab, and H. H. Zedan, "Kojic acid repurposing as a pancreatic lipase inhibitor and the optimization of its production from a local Aspergillus oryzae soil isolate", BMC Biotechnology , vol. 20, issue 1, pp. 1-16, 2020.
L
Laura Cif, K. E. Barwick, J. - P. Lin, M. Sa, L. Abela, D. Demailly, S. Malhotra, Wui K Chong, D. Steel, and L. Selim, "KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation", brain, vol. 143, issue 11, pp. 3242-3261, 2020.
M
M. A. Mahmoud, and Y.E.E.Gamal, "Kinetics of Ion Formation in Rubidium Vapour Excited by Nanosecond Resonant Laser Pulses", 32nd ICPIG, Iași, Romania, pp. 1-4, 2015. 63-5_icpig__2015__conference.pdf
M.Y.H.Farag, S.H.Fricke, and K.W.McVoy, "Kinematic aspects of alpha + 12 C coincidence spectra from 197 Au ( 20Ne, alpha + 12C ) 201TL at 11 MeV/A ", Internal Reprint Mad / NT / 88-00, Physics Department, University of Wisconsin, Madison, USA , 1988.
MA, E. - D., E. H. MS, and A. H. RM, "Kallin Syndrome associated with vitiligo", Clinical and experimental dermatology , vol. 40, pp. 35-38, 2015.
Madani, A. A., "Knowledge-driven GIS modeling technique for gold exploration, Bulghah gold mine area, Saudi Arabia", The Egyptian Journal of Remote Sensing and Space Science, vol. 14, no. 2: Elsevier, pp. 91–97, 2011. Abstract
n/a
Magid, H. A. M., R. E. A. Sabrah, A. R. H. El Nadi, S. I. Abdel-Aal, and R. K. Rabic, "Kinetics of biodegradation rates of chicken manure and municipal refuse in a sandy soil", Journal of Arid Environments, vol. 28, issue 2: Academic Press, pp. 163-171, 1994. Abstract
n/a
Magid, H. A. M., R. E. A. Sabrah, A. R. H. El Nadi, S. I. Abdel-Aal, and R. K. Rabic, "Kinetics of biodegradation rates of chicken manure and municipal refuse in a sandy soil", Journal of Arid Environments, vol. 28, issue 2: Academic Press, pp. 163-171, 1994. Abstract
n/a
Mahmoud, M. A., and Y. E. E. Gamal, "Kinetics of plasma formation in sodium vapor excited by nanosecond resonant laser pulses", Indian J Phys , vol. 86, issue 7, pp. 659–666 , 2012. fulltext1indian_journal_of_pure_physics.pdf
Mahmoud, H. K., Y. El Nahas, M. Abdel Moaty, R. Abdel Fattah, M. El Emary, and W. El Metnawy, "Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.", International journal of biomedical science : IJBS, vol. 5, issue 3, pp. 223-8, 2009 Sep. Abstract

PURPOSE: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML.

METHODS: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cytogenetic analysis was performed at diagnosis and every 6 months. Molecular monitoring by RT-QPCR was performed at diagnosis and every 3 months during a median follow-up period (FUp) of 26 months. Mutation detection of ABL domain was performed by ASO-PCR.

RESULTS: Hematological response was 98% after three months of IM therapy. Out of 95 patients 59 showed 2 log reduction of BCR-ABL/ABL ratio after 6 months of whom 49 (83%) had complete cytogenetic response (CCyR) and 42 (71%) had major molecular response (MMR) at 12 months. BCR-ABL transcripts remained undetectable in 22 patients (39%) at 26 months. Among the remaining 34 patients not achieving 2 log reduction at 6 months only 5 (15%) had CCyR and MMR by 12 months. ABL domain mutations were detected in 11/15 (73%) resistant and suboptimal responding patients. Achieving 2 log reduction after 6 months of IM therapy significantly correlated with sustained cytogenetic and molecular responses (p<0.0001), with PFS at 2 years (p<0.03) and inversely with ABL gene mutations (p<0.001).

DISCUSSION: These data demonstrated the predictive value of early molecular response to IM in CPCML regarding disease course and PFS. A 2 log reduction at 6 months of IM treatment could be a cut off level predicting resistance, CCyR, or suggesting IM dose modification.

Mahmoud, H., Y. El Nahas, M. Abdel Moaty, R. Abdel Fattah, M. El Emary, and W. El Metnawy, "Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.", International journal of biomedical science : IJBS, vol. 5, issue 3, pp. 223-8, 2009 Sep. Abstract

PURPOSE: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML.

METHODS: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cytogenetic analysis was performed at diagnosis and every 6 months. Molecular monitoring by RT-QPCR was performed at diagnosis and every 3 months during a median follow-up period (FUp) of 26 months. Mutation detection of ABL domain was performed by ASO-PCR.

RESULTS: Hematological response was 98% after three months of IM therapy. Out of 95 patients 59 showed 2 log reduction of BCR-ABL/ABL ratio after 6 months of whom 49 (83%) had complete cytogenetic response (CCyR) and 42 (71%) had major molecular response (MMR) at 12 months. BCR-ABL transcripts remained undetectable in 22 patients (39%) at 26 months. Among the remaining 34 patients not achieving 2 log reduction at 6 months only 5 (15%) had CCyR and MMR by 12 months. ABL domain mutations were detected in 11/15 (73%) resistant and suboptimal responding patients. Achieving 2 log reduction after 6 months of IM therapy significantly correlated with sustained cytogenetic and molecular responses (p<0.0001), with PFS at 2 years (p<0.03) and inversely with ABL gene mutations (p<0.001).

DISCUSSION: These data demonstrated the predictive value of early molecular response to IM in CPCML regarding disease course and PFS. A 2 log reduction at 6 months of IM treatment could be a cut off level predicting resistance, CCyR, or suggesting IM dose modification.